News ZEUS delivers a bolt of pain to Novo Nordisk Novo Nordisk's IL-6 inhibitor ziltivekimab has failed the phase 3 ZEUS trial in heart disease, denting its bid to expand into new therapeutic areas.
News Pfizer cues up vitiligo filing for Litfulo after phase 3 win Pfizer's JAK inhibitor Litfulo hits the mark in vitiligo, setting up filings, as Incyte claims EU approval for Opzelura in atopic dermatitis.
News UK patient first in world to get novel lung cancer vaccine A woman from the Wirral in the UK has become the first patient in the world to receive an experimental, personalised lung cancer vaccine.
News Simple blood test could aid in global TB fight A blood test for tuberculosis that can distinguish between dormant and active infections has shown promise in a clinical trial.
News Altimmune alcohol use disorder drug hits the mark in phase 2 Altimmune's pemvidutide has been shown to reduce drinking in people with alcohol use disorder, adding to the evidence for GLP-1 drugs in this setting.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.